HUMA Stock Overview Engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Humacyte, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Humacyte Historical stock prices Current Share Price US$4.64 52 Week High US$9.97 52 Week Low US$2.48 Beta 1.38 1 Month Change 3.34% 3 Month Change -24.18% 1 Year Change 61.11% 3 Year Change -40.74% 5 Year Change n/a Change since IPO -52.02%
Recent News & Updates See more updates
Humacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade) Dec 23
Humacyte Announces FDA Approval of SYMVESS for the Treatment of Extremity Vascular Trauma Dec 20
Humacyte: FDA Waiting Game Bleeding Company Dry Dec 14
Humacyte, Inc. Announces Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injury Published in Jama Surgery Nov 21 Holzer & Holzer, LLC Files Class Action Lawsuit Against Humacyte, Inc Nov 20
Humacyte, Inc. Presents Preclinical Results of Small-Diameter ATEV™? for Coronary Artery Bypass Grafting at American Heart Association's Scientific Sessions 2024 Nov 19
Consensus revenue estimates fall by 32% Nov 15 Humacyte, Inc. has filed a Follow-on Equity Offering. Nov 14
New minor risk - Profitability Nov 11
Forecast to breakeven in 2026 Nov 10
Humacyte, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Nov 06
Humacyte Announces Presentation of Positive Results from V007 Phase 3 Av Access Clinical Trial At the American Society of Nephrology’S Kidney Week 2024 Oct 28 Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $30.00001 million. Oct 05
Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $30.00001 million. Oct 04
Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Sep 26 Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Sep 25
Humacyte: Navigating The FDA Uncertainty And ATEV's Potential Sep 24
Humacyte, Inc. Announces Allowance of U.S. Patent Covering BioVascular Pancreas Sep 21
Price target increased by 20% to US$13.17 Sep 11
Key Executive notifies of intention to sell stock Aug 29
Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely? Aug 16
New minor risk - Insider selling Aug 15
Humacyte, Inc. Acellular Tissue Engineered Vessel Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis Jul 31
Humacyte: Pioneering Vascular Solutions With High-Stakes Potential Jul 17
Price target increased by 13% to US$9.30 Jul 16
Consensus revenue estimates increase by 13% Jul 16
Humacyte Announces the Addition of John P. Bamforth and Keith Anthony Jones to the Company’s Board of Directors Jul 16
High number of new directors Jul 12
Humacyte, Inc.(NasdaqGS:HUMA) dropped from Russell Small Cap Comp Value Index Jul 03
Humacyte, Inc. Presents Positive Preclinical Data for Its Biovascular Pancreas (Bvp™?) Program Jun 25
Independent Chairman of the Board exercised options to buy US$234k worth of stock. Jun 18
Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation Jun 05
Chief Operating Officer recently sold US$502k worth of stock Jun 04
Chief Operating Officer notifies of intention to sell stock Jun 02
Independent Director recently bought US$668k worth of stock May 16
Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High May 14
Humacyte, Inc. to Report Q1, 2024 Results on May 10, 2024 May 08
Humacyte, Inc., Annual General Meeting, Jun 11, 2024 May 01
Consensus revenue estimates decrease by 12%, EPS upgraded Apr 04
Price target increased by 7.1% to US$7.50 Mar 29
New major risk - Revenue and earnings growth Mar 23
Humacyte, Inc. to Report Q4, 2023 Results on Mar 22, 2024 Mar 19 Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million. Mar 02
New minor risk - Shareholder dilution Mar 01 Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.
Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely? Feb 14
Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application Feb 09
New minor risk - Share price stability Feb 08
Consensus revenue estimates decrease by 12% Feb 06
Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel (Hav) for the Treatment of Vascular Trauma Dec 13
Humacyte, Inc. Announces Presentations of Positive Clinical Results of the Human Acellular Vessel™? (HAV™?) in the Treatment of Vascular Trauma Nov 18
Humacyte, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
Humacyte, Inc. Publishes Preclinical Results Showing Human Acellular Vessel™? Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model Oct 17
Founder exercised options to buy US$280k worth of stock. Oct 12
Humacyte, Inc. Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™? (HAV™?) in Treatment of Patients with Vascular Trauma Sep 13
Humacyte, Inc. Announces the Presentation of Results from FDA Regulated, Investigator-Sponsored Clinical Study Conducted At the Mayo Clinic Sep 12
Consensus revenue estimates fall by 33% Aug 21
Humacyte, Inc. Presents Clinical Performance of Human Acellular Vessel (HAV) from Ukrainian Humanitarian Program Aug 17
New major risk - Revenue size Aug 14
First half 2023 earnings released: US$0.58 loss per share (vs US$0.17 profit in 1H 2022) Aug 14
Humacyte, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 08
Humacyte, Inc. Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel Aug 04
Humacyte, Inc. Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel(Tm) (Hav(Tm)) for Vascular Trauma Repair Jul 27
Chief Operating Officer exercised options to buy US$240k worth of stock. May 28
First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.19 loss in 1Q 2022) May 13
Humacyte, Inc. to Report Q1, 2023 Results on May 12, 2023 May 06
Price target decreased by 24% to US$7.35 Apr 23
Consensus revenue estimates decrease by 45%, EPS upgraded Mar 31
Price target decreased by 15% to US$9.46 Mar 25
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 25
Investor sentiment deteriorates as stock falls 16% Mar 13
Founder exercised options to buy US$321k worth of stock. Mar 07
Investor sentiment improves as stock rises 15% Feb 01
Humacyte, Inc. Announces Publication of 6-Year Outcomes of Phase 2 Study of Human-Tissue Engineered Blood Vessels for Peripheral Arterial Bypass, in Journal of Vascular Surgery – Vascular Science Jan 25
Key Executive recently bought US$52k worth of stock Dec 21
Investor sentiment deteriorated over the past week Dec 15
Consensus EPS estimates fall by 13% Nov 17
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 16 Shareholder Returns HUMA US Biotechs US Market 7D 6.9% -3.8% -2.7% 1Y 61.1% -2.6% 23.4%
See full shareholder returns
Return vs Market: HUMA exceeded the US Market which returned 23.4% over the past year.
Price Volatility Is HUMA's price volatile compared to industry and market? HUMA volatility HUMA Average Weekly Movement 15.7% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: HUMA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HUMA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.
Show more Humacyte, Inc. Fundamentals Summary How do Humacyte's earnings and revenue compare to its market cap? HUMA fundamental statistics Market cap US$597.02m Earnings (TTM ) -US$152.87m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) HUMA income statement (TTM ) Revenue US$0 Cost of Revenue US$77.40m Gross Profit -US$77.40m Other Expenses US$75.47m Earnings -US$152.87m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.19 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -97.9%
How did HUMA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 21:55 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Humacyte, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Bruce Jackson Benchmark Company Michael Gorman BTIG Kristen Kluska Cantor Fitzgerald & Co.
Show 6 more analysts 
